Ones To Watch News
Refine Search
Pharmaceutical
Ireland-headquartered pioneering inflammasone company Inflazome has announced the appointment of Dr Thomas Jung as its chief medical officer. 30 November 2018
Pharmaceutical
In what is a second buy this year for the company, Cambrex Corp (NYSE: CBM), a manufacturer of active pharmaceutical ingredients (APIs) and finished dosage forms, announced it has entered into a definitive agreement to acquire fellow USA-based Avista Pharma Solutions, a contract development, manufacturing, and testing organization. 23 November 2018
Biotechnology
Sitryx, a new, Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces it has closed its Series A financing round. 8 October 2018
Pharmaceutical
In a major restructuring, privately-held Switzerland-based healthcare company Roivant Sciences has created two new business units, Roivant Pharma and Roivant Health, to focus its efforts on accelerating the launch of new innovative healthcare companies, including ‘Vants’ oriented around earlier-stage scientific platforms. 28 June 2018
Biotechnology
AmideBio, a privately held US biotech company, has announced that Dr Pawel Fludzinski has joined the company as its new chief executive. 17 May 2018
Biosimilars
A new name is now listed among the member companies of the official trade association for the European generic, biosimilar and value-added pharmaceutical industries. 8 May 2018
Biotechnology
Despite announcing that positive trial results had been published on its lead cancer drug candidate, Polish biotech firm Selvita saw its share price dip 1.33% to 59.20 zlotys this morning. 16 April 2018
Biotechnology
Eli Lilly has offloaded three non-alcoholic steatohepatitis (NASH) programs to Sino-American biotech startup Terns Pharmaceuticals, which will take on global development and commercialization of the small molecule candidates. 6 April 2018
Pharmaceutical
An absence of comprehensive data did not prevent Italian family-owned drugmaker Chiesi Farmaceutici from receiving Marketing Authorization (MA) for Lamzede (velmanase alfa). 4 April 2018
Biotechnology
US privately-held biotech start-up Sigilon Therapeutics has signed its first major deal for the use of its encapsulated cell therapy Afibromer. 4 April 2018
Biotechnology
Israeli biotech VBL Therapeutics has granted Japanese company NanoCarrier an exclusive license to develop and commercialize the gene therapy ofranergene obadenovec (VB-111) in Japan. 6 November 2017
Biotechnology
Japan-based start-up Noile-Immune Biotech has entered into a collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) with Japan’s largest drugmaker. 4 September 2017
Pharmaceutical
Eagle Pharmaceuticals has announced the US Food and Drug Administration will review its filing for Ryanodex (dantrolene sodium), and has given the therapy priority review designation. 29 March 2017
Biotechnology
PsiOxus Therapeutics, an Imperial Innovations portfolio company, has out-licensed exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus which may serve as a novel mechanism to address solid tumors. 20 December 2016
Biosimilars
US drugmaker Eagle Pharmaceuticals has signed a definitive agreement to acquire an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how. 12 November 2016
Biotechnology
US drug maker Bristol-Myers Squibb has announced an exclusive clinical collaboration with England’s immune-oncology company PsiOxus Therapeutics, it has been announced. 1 July 2016
Biotechnology
Minerva Neurosciences saw its shares sky-rocket as much as 183% to $10.03 in heavy volume this morning, after the company released strong mid-stage results with it schizophrenia drug candidate. 26 May 2016
Biotechnology
Addex Therapeutics says that the US Food and Drug Administration has granted orphan drug designation to dipraglurant for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). 4 January 2016
Biotechnology
The key message from European Partnering and Investment Conference in biotech, held yesterday in London, was that it is essential to prove the commercial viability of propositions, not simply that they are a good idea, from CNS drugs to Ebola testing. 3 October 2014
Pharmaceutical
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream submitted by Arcutis Biotherapies.
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze